AstraZeneca Targets $80bn Sales By 2030 But Analysts Still To Be Convinced
Executive Summary
The UK company has unveiled a new strategy for 2030 and beyond but analysts' forecasts fall around $15bn short of the company’s own projections.
Topics
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC150297
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC150297
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.